Maxime Verhoeven

151 Cost-effectiveness of treat-to-target strategies over 5 years Supplementary Table 4 (continued) TCZ+MTX (n=106) TCZ (n=103) MTX (n=108) Total productivity loss costs $ - year 1 - year 2 - year 3 - year 4 - year 5 - over 5 years - over 2 years 2,500 (2,100 to 3,000) 3,700 (3,000 to 4,400) 3,200 (2,500 to 3,800) 2,100 (1,700 to 2,600) 600 (300 to 1,100) 12,100 (9,600 to 14,600) 6,200 (5,100 to 7,300) 2,300 (1,800 to 2,800) 3,200 (2,500 to 3,900) 2,800 (2,100 to 3,400) 1,900 (1,400 to 2,400) 600 (1,100 to 1,300) 10,700 (8,400 to 13,200) 5,500 (4,400 to 6,600) 2,500 (2,100 to 3,000) 3,300 (2,600 to 4,000) 2,800 (2,200 to 3,400) 1,900 (1,500 to 2,300) 400 (200 to 700) 10,900 (8,700 to 13,200) 5,800 (4,700 to 6,900) Direct healthcare costs - year 1 - year 2 - year 3 - year 4 - year 5 - over 5 years - over 2 years 6,100 (5,500 to 6,700) 18,700 (14,800 to 22,800) 16,500 (13,200 to 19,800) 12,000 (10,000 to 14,000) 5,200 (4,600 to 5,900) 58,400 (49,200 to 67,900) 24,800 (20,900 to 31,400) 7,200 (6,200 to 8,500) 7,000 (5,700 to 8,500) 6,900 (5,800 to 8,200) 6,700 (6,000 to 7,600) 6,300 (5,700 to 6,900) 34,200 (30,600 to 38,200) 14,300 (12,500 to 16,200) 7,000 (6,200 to 7,900) 8,700 (6,300 to 11,400) 8,200 (6,300 to 10,400) 7,300 (6,100 to 8,600) 5,900 (5,400 to 6,300) 37,100 (31,500 to 43,500) 15,700 (13,200 to 18,600) Indirect non-healthcare costs - year 1 - year 2 - year 3 - year 4 - year 5 - over 5 years - over 2 years 1,100 (800 to 1,400) 300 (200 to 500) 700 (600 to 900) 1,600 (1,400 to 1,700) 2,800 (2,500 to 3,000) 6,500 (6,000 to 7,100) 1,500 (1,100 to 1,800) 1,600 (1,000 to 2,300) 700 (500 to 900) 1,000 (900 to 1,200) 1,800 (1,600 to 1,900) 2,800 (2,500 to 3,100) 7,900 (7,000 to 8,800) 2,300 (1,600 to 3,100) 1,500 (1,100 to 2,000) 600 (400 to 700) 1,300 (1,100 to 1,400) 2,800 (2,500 to 3,100) 5,000 (4,300 to 5,700) 11,100 (9,800 to 1,500) 2,100 (1,600 to 2,600) QALYs - year 1 - year 2 - year 3 - year 4 - year 5 - over 5 years - over 2 years 0.69 (0.64 to 0.73) 0.84 (0.81 to 0.86) 0.76 (0.71 to 0.81) 0.76 (0.71 to 0.80) 0.74 (0.70 to 0.78) 3.78 (3.66 to 3.91) 1.52 (1.46 to 1.58) 0.70 (0.67 to 0.74) 0.79 (0.75 to 0.82) 0.77 (0.73 to 0.80) 0.73 (0.68 to 0.77) 0.69 (0.65 to 0.74) 3.69 (3.56 to 3.81) 1.49 (1.43 to 1.56) 0.64 (0.59 to 0.68) 0.83 (0.80 to 0.85) 0.74 (0.70 to 0.79) 0.77 (0.73 to 0.80) 0.74 (0.70 to 0.79) 3.72 (3.61 to 3.84) 1.47 (1.42 to 1.51) Outcomes based on single imputation nested in 10,000 bootstraps; costs expressed in euro’s. Undiscounted values. TCZ+MTX= initiation of tocilizumab + methotrexate strategy group; TCZ= initiation of tocilizumab + placebo- methotrexate strategy group; MTX= initiation of methotrexate + placebo-tocilizumab strategy group; total medication costs= all RA medication costs; other medication costs= all RA medication costs, without bDMARDs; productivity loss costs= costs related to work loss or being less productive; # = using human capital approach; $ = using friction cost approach, only counting costs for a period of absence up to 85 days; direct healthcare costs= all costs related to healthcare, also for other diseases (RA medication costs excluded); indirect non healthcare costs= costs related to patient and family (e.g., travel cost, buying stair lift, etc.); QALY= quality-adjusted life years [range 0-1, 1= full health]. 7